

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial

Protocol summary

Study aim

Investigating the effect of adding aripiprazole as adjunctive therapy in the treatment of obsessive-compulsive symptoms in patients with bipolar disorder

Design

This double-blind clinical trial study has a parallel control group, where the patient and the researcher do not know the type of drug received. 23 patients are allocated in each group. Randomization will be done using a table of random numbers.

Settings and conduct

This study is a double-blind clinical trial in which the patient and the researcher do not know the type of drug received. This study will be conducted on all qualified patients under treatment referring to Golestan Hospital in the period of 2021-2022

Participants/Inclusion and exclusion criteria

Included criteria: age 18 to 60 years, confirmation of bipolar disorder based on DSM-5 criteria. Exclusion criteria: not having cardiovascular, respiratory, kidney or digestive diseases; Not pregnant, not suffering from drug or alcohol abuse

Intervention groups

Intervention group: They will receive quetiapine with the addition of sodium valproate and aripiprazole.

Aripiprazole will be added to the patients' current medications with an initial dose of 5 mg per day, and then the dose will be increased by 5 mg per week to 20 mg per day. The dose of aripiprazole will be adjusted based on the patient's response or patient tolerance. The effect of the drug will be evaluated in weeks 4, 8 and 12. Control group: they will receive quetiapine plus sodium valproate and will be evaluated in weeks 8 and 12.

Main outcome variables

Severity of obsession, severity of depression, severity of mania

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230814059145N1**

Registration date: **2023-10-22, 1402/07/30**

Registration timing: **prospective**

Last update: **2023-10-22, 1402/07/30**

Update count: **0**

Registration date

2023-10-22, 1402/07/30

Registrant information

Name

Rakhshan Abiri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 4428 6943

Email address

abirirakhshan@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-11-01, 1402/08/10

Expected recruitment end date

2023-12-31, 1402/10/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial

Public title

Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in bipolar disorder

Purpose

Other

Inclusion/Exclusion criteria**Inclusion criteria:**

Age 18 to 60 years Confirmation of bipolar disorder based on DSM-5 criteria

Exclusion criteria:

Not having cardiovascular, respiratory, kidney or digestive diseases Not pregnant Not suffering from drug or alcohol abuse

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: **46**

Randomization (investigator's opinion)

Randomized

Randomization description

The method of randomization is the use of random numbers that are used from random sequence generation software, which refers to the method used to perform a random sequence on the participants in the study, in such a way that before allocating the individual, the allocation group The finding is not clear. By using sealed opaque mail envelopes with a random sequence, each of the generated random sequences is recorded on a card and the cards are placed inside the mail envelopes in order. In order to maintain the random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lid of the letter envelopes is glued and placed in a box. At the time of starting the registration of participants, based on the order in which eligible participants entered the study, one of the envelopes will be opened and the assigned group of that participant will be revealed.

Blinding (investigator's opinion)

Double blinded

Blinding description

The patients are randomly divided into two control and intervention groups, the control group receives placebo in addition to the drugs consumed, and the intervention group receives aripiprazole in addition to the drugs consumed, and the main partner of the project and the patient remain unaware of the type of treatment.

Placebo

Used

Assignment

Other

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Ahvaz Jundishapur University of Medical Sciences

Street address

Ahvaz, Golestan St., Farvardin Blvd., Jundishapur University of Medical Sciences, Ahvaz

City

Ahvaz

Province

Khuzestan

Postal code

6135715794

Approval date

2022-11-01, 1401/08/10

Ethics committee reference number

IR.AJUMS.HGOLESTAN.REC.1401.116

Health conditions studied**1****Description of health condition studied**

Bipolar disorder

ICD-10 code

F31

ICD-10 code description

Bipolar disorder

Primary outcomes**1****Description**

Depression

Timepoint

Before the intervention and weeks 4, 8 and 12 after the intervention

Method of measurement

Hamilton

2**Description**

Symptoms of mania

Timepoint

Before the intervention and weeks 4, 8 and 12 after the intervention

Method of measurement

Young mania rating scale

3

Description

Obsessive compulsive symptoms

Timepoint

Before the intervention and weeks 4, 8 and 12 after the intervention

Method of measurement

Yale brown obsessive compulsive scale scoring

Secondary outcomes

1

Description

Drug complication

Timepoint

Before the intervention and weeks 4, 8 and 12 after the intervention

Method of measurement

Abnormal Involuntary Movement scale

Intervention groups

1

Description

Intervention group: The intervention group will receive quetiapine with the addition of sodium valproate and aripiprazole. Aripiprazole will be added to patients' current medications at an initial dose of 5 mg per day, and then the dose will be increased by 5 mg per week up to 20 mg per day. Aripiprazole is produced by Actoverco pharmaceutical company.

Category

Treatment - Drugs

2

Description

Control group: they will receive quetiapine plus sodium valproate and placebo

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Golestan Hospital

Full name of responsible person

Hamzeh rostami

Street address

Golestan hospital, Golestan street

City

Ahvaz

Province

Khuzestan

Postal code

6135733118

Phone

+98 61 3374 3001

Fax

+98 61 3374 3030

Email

Golestanjpspital@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Mehrnoosh Zakerkish

Street address

Ahvaz Jundishapur University of Medical Sciences,
Farvardin Blvd, Golestan Ave, Ahvaz Ahvaz

City

Ahvaz

Province

Khuzestan

Postal code

6135715794

Phone

+98 61 3374 3038

Email

zakerkish.m@ajums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ahvaz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Maryam Poorshams

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Psychiatrics

Street address

Golestan hospital, Farvardin Blvd, Golestan Ave,
Ahvaz Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

6135715794

Phone

+98 61 3374 3038

Email

poorshams@ajums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Hamzeh Rostami

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Psychiatrics

Street address

Golestan hospital, Farvardin Blvd, Golestan Ave,
Ahvaz Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

6135715794

Phone

+98 61 3374 3038

Email

rostami.h@ajums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Ahvaz University of Medical Sciences

Full name of responsible person

Rakhshan Abiri

Position

Resident

Latest degree

Specialist

Other areas of specialty/work

Psychiatrics

Street address

Golestan hospital, Farvardin Blvd, Golestan Ave,
Ahvaz Ahvaz

City

Ahvaz

Province

Khouzestan

Postal code

6135715794

Phone

+98 61 3374 3038

Email

abirirakhshan@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available